Nonmyeloablative allogeneic hematopoietic stem cell transplantation for metastatic breast cancer

Clinical Breast Cancer

Volumn 4, Issue 1, 2003, Pages 39-45

  Bishop, Michael R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adoptive cellular therapy; Chimerism; Graft versus host disease; Graft versus tumor effect; Reduced intensity conditioning regimens; T cells

Indexed keywords

ALEMTUZUMAB; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CARMUSTINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOTOXIC AGENT; DNA VACCINE; FLUDARABINE; MELPHALAN; RECOMBINANT INTERLEUKIN 2; TAXANE DERIVATIVE; THIOTEPA; TRASTUZUMAB;

ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER MORTALITY; CHIMERA; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; ERADICATION THERAPY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LABORATORY TEST; LYMPHOID CELL; LYMPHOPROLIFERATIVE DISEASE; METASTASIS; MORBIDITY; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; REVIEW; T LYMPHOCYTE;

EID: 0038783099     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2003.n.010     Document Type: Review

References (58)

1. Armitage JO. Bone marrow transplantation. N Engl J Med 1994; 330:827-838.
2. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986; 4:1162-1170.
3. Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15:1870-1879.
4. Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 2000; 342:1069-1076.
5. Buckner CD, Clift RA, Fefer A, et al. Marrow transplantation for the treatment of acute leukemia using HL-A-identical siblings. Transplant Proc 1974; 6:365-366.
6. Baranov A, Gale RP, Guskova A, et al. Bone marrow transplantation after the Chernobyl nuclear accident. N Engl J Med 1989; 321:205-212.
7. Bearman SI, Appelbaum FR, Back A, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6:1562-1568.
8. McCarthy NJ, Bishop MR. Nonmyeloablative allogeneic stem cell transplantation: early promise and limitations. Oncologist 2000; 5:487-496.
9. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91:756-763.
10. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stemcell transplantation. N Engl J Med 2000; 343:750-758.
11. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75:555-562.
12. Maraninchi D, Gluckman E, Blaise D, et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet 1987; 2:175-178.
13. Sullivan KM, Storb R, Buckner CD, et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. N Engl J Med 1989; 320:828-834.
14. Weiden PL, Sullivan KM, Flournoy N, et al. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 1981; 304:1529-1533.
15. Fefer A, Cheever MA, Greenberg PD. Identical-twin (syngeneic) marrow transplantation for hematologic cancers. J Natl Cancer Inst 1986; 76:1269-1273.
16. Gale RP, Horowitz MM, Ash RC, et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994; 120:646-652.
17. Porter DL, Roth MS, MeGarigle C, et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994; 330:100-106.
18. Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86:1261-1268.
19. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86:2041-2050.
20. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15:433-444.
21. Verdegaal EM, Huinink DB, Hoogstraten C, et al. Isolation of broadly reactive, tumor-specific, HLA Class-I restricted CTL from blood lymphocytes of a breast cancer patient. Hum Immunol 1999; 60:1195-1206.
22. Linehan DC, Goedegebuure PS, Peoples GE, et al. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J Immunol 1995; 155:4486-4491.
23. Baxevanis CN, Dedoussis GV, Papadopoulos NG, et al. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer. Cancer 1994; 74:1275-1282.
24. Morecki S, Yacovlev E, Diab A, et al. Allogeneic cell therapy for a murine mammary carcinoma. Cancer Res 1998; 58:3891-3895.
25. Morecki S, Yacovlev E, Gelfand Y, et al. Cell therapy with preimmunized effector cells mismatched for minor histocompatible antigens in the treatment of a murine mammary carcinoma. J Immunother 2001; 24:114-121.
26. Fuzak J, Jung U, Foley J, et al. Allospecific Tc2 cells mediate a graft-versus-tumor effect without inducing ongoing GVHD in a routine model of metastatic breast cancer. Blood 2000; 96:551a (Abstract #2367).
27. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338:1272-1278.
28. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271:907-913.
29. Childs RW Bradstock KF, Gottlieb D, et al. Non-myeloablative allogeneic stem cell transplantation as immunotherapy for metastatic melanoma: Results of a pilot study. Blood 2000; 96:353b (Abstract #5277).
30. Eibl B, Schwaighofer H, Nachbaur D, et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88:1501-1508.
31. Ueno NT, Rondon G, Mirza NQ, et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 1998; 16:986-993.
32. Or R, Ackerstein A, Nagler A, et al. Allogeneic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation: a clinical pilot study. Cytokines Cell Mol Ther 1998; 4:1-6.
33. Giralt SA, Kolb HJ. Donor lymphocyte infusions. Curr Opin Oncol 1996; 8:96-102.
34. Hiruma K, Hirsch R, Patchen M, et al. Effects of anti-CD3 monoclonal antibody on engraftment of T-cell-depleted bone marrow allografts in mice: host T-cell suppression, growth factors, and space. Blood 1992; 79:3050-3058.
35. Yu C, Storb R, Mathey B, et al. DLA-identical bone marrow grafts after low-dose total body irradiation: effects of high-dose corticosteroids and cyclosporine on engraftment. Blood 1995; 86:4376-4381.
36. Sykes M, Szot GL, Swenson KA, et al. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med 1997; 3:783-787.
37. Quesenberry PJ, Stewart MF, Peters S, et al. Engraftment of hematopoietic stem cells in nonmyeloablated and myeloablated hosts. Stem Cells 1997; 15(suppl 1):167-169.
38. Petrus MJ, Williams JF, Eckhaus MA, et al. An immunoablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD. Biol Blood Marrow Transplant 2000; 6:182-189.
39. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89:4531-4536.
40. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91:756-763.
41. Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine- based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16:2817-2824.
42. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94:3234-3241.
43. Spitzer TR, McAfee S, Sackstein R, et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000; 6:309-320.
44. Sandmaier BM, McSweeney P, Yu C, et al. Nonmyeloablative transplants: preclinical and clinical results. Semin Oncol 2000; 27(suppl 5):78-81.
45. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
46. Rizzieri DA, Long GD, Vredenburgh JJ, et al. Non-myeloablative allogeneic transplantation using T depleted matched sibling peripheral blood stem cells. Blood 2001; 98:420a (Abstract #1764).
47. Bishop MR, Marchigiani D, Kasten-Sportes C, et al. Pre-transplant quantitation of host T-cells as a method to determine adequate host immune depletion for successful engraftment of T-cell depleted allografts after reduced-intensity conditioning. Blood 2001; 98:189a (Abstract #792).
48. Bregni M, Dodero A, Peccatori J, et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99:4234-4236.
49. Cheng YE, Ueno NT. Non-myeloablative allogeneic peripheral blood progenitor cell transplantation for metastatic breast cancer and metastatic renal cell carcinoma: the M.D. Anderson Cancer Center experience. Haematologica 2002; 87(suppl 1):6-9.
50. Carella AM, Corsetti MT, Beltrami G, et al. Autografting and non-myeloablative allogeneic stem cell transplantation in metastatic breast cancer. Haematologica 2002; 87 (suppl 1):10-11.
51. Blaise D, Faucher C, Bay JO, et al. Allogeneic immunotherapy in patients suffering from advanced solid tumors. Haematologica 2002; 87(suppl 1):15-16.
52. Siena S, Pedrazzoli P, Giorgiani G, et al. Allogeneic hematopoietic stem cell transplantation for solid tumors other than renal cell cancer. Haematologica 2002; 87 (suppl 1):17-20.
53. Pedrazzoli P, Da Prada GA, Giorgiani G, et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 2002; 94:2409-2415.
54. Kummar S, Ishii A, Yang HK, et al. Modulation of graft-versus-tumor effects in a murine allogeneic bone marrow transplantation model by tumor-derived transforming growth factor-betaI. Biol Blood Marrow Transplant 2001; 7:25-30
55. Urbano-Ispizua A, Schmitz N, de Witte T, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2002; 29:639-646.
56. zum Buschenfelde CM, Hermann C, Schmidt B, et al. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells. Cancer Res 2002; 62:2244-2247.
57. Disis ML, Gooley TA, Rinn K, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002; 20:2624-2632.
58. Niethammer AG, Xiang R, Becker JC, et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth.